拉萨疼 全身无力(菏泽体检去哪里) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

WASHINGTON, July 12 (Xinhua) -- Two U.S. astronauts stepped out the International Space Station on Tuesday to retrieve a failed ammonia pump, which is the last spacewalk of the shuttle era, NASA announced.Space station astronauts Mike Fossum and Ron Garan completed the six-hour, 31-minute spacewalk at 3:53 p.m. EDT (1953 GMT). The duo retrieved a pump module from an external stowage platform on station and store it in shuttle Atlantis' cargo bay for return to Earth.The pump module failed in 2010, shutting down half of the space station's cooling system. Engineers will evaluate the module to determine the cause of the failure and plan to refurbish it for use as a spare.The astronauts also attached a Robotic Refueling Module experiment to the space station, which aims to test technologies for repairing and refueling satellites in space.It was the 249th spacewalk by U.S. astronauts and the 160th spacewalk in support of space station assembly and maintenance, totaling 1009 hours, nine minutes.Atlantis lifted off on Friday morning from Kennedy Space Center in Florida, on the 135th and final flight in NASA's shuttle program. Its return to the earth later this month will mark the end of the 30-year shuttle program.

SAN FRANCISCO, June 17 (Xinhua) -- A new research released on Friday shows that smartphone users in the United States are consuming more data than ever, growing by 89 percent in the first quarter on a year-over-year basis.According to data from marketing company Nielsen, the amount of data the average smartphone user consumes per month is 435 Megabytes (MB) in the first quarter of 2011, compared with 230 MB in the same period last year.As for the distribution of data consumption, data usage for the top 10 percent of smartphone users is up 109 percent while the top 1 percent has grown their usage by 155 percent from 1.8 Gigabytes (GB) in the first quarter of 2010 to over 4.6 GB this year.The research said consumers with iPhones and Android smartphones consume the most data, which is driven by app-friendly operating systems like Apple's iOS and Google's Android. Windows Phone 7 users doubled their usage over the fourth quarter of 2010 and the first quarter of 2011, perhaps due to growth in the number of applications available.Meanwhile, the cost per MB for smartphones has dropped by 46 percent over the last year, from 14 cents per MB to 8 cents, said the research.According to Internet marketing research company comScore, in the first quarter of 2011, 234 million Americans ages 13 and older used mobile devices, 74,6 million of whom are smartphone users.

OTTAWA, Sept. 29 (Xinhua) -- Climate change could cost Canada billions of dollars a year by the end of this decade, a government funded study group announced Thursday.The National Round Table on the Environment and the Economy said the cost of climate change for Canada could start at roughly 5 billion Canadian dollars per year in 2020 and increase to between 21 billion and 43 billion per year by 2050. Those costs would come from shoreline damage, public health problems, and disruptions to the economy.It also predicted a slight increase in deaths in major cities from heat and air pollution.The round table researchers estimated the cost of climate change is expected to be roughly 0.8 percent to 1.0 percent of GDP -- or 43 billion Canadian dollars a year -- by 2050, if the problem is allowed to worsen.But the report did not address possible benefits, such as reduced demand for hea

来源：资阳报